A Two-Step Target Binding and Selectivity Support Vector Machines Approach for Virtual Screening of Dopamine Receptor Subtype-Selective Ligands

Target selective drugs, such as dopamine receptor (DR) subtype selective ligands, are developed for enhanced therapeutics and reduced side effects. In silico methods have been explored for searching DR selective ligands, but encountered difficulties associated with high subtype similarity and ligand structural diversity. Machine learning methods have shown promising potential in searching target selective compounds. Their target selective capability can be further enhanced. In this work, we introduced a new two-step support vector machines target-binding and selectivity screening method for searching DR subtype-selective ligands, which was tested together with three previously-used machine learning methods for searching D1, D2, D3 and D4 selective ligands. It correctly identified 50.6%–88.0% of the 21–408 subtype selective and 71.7%–81.0% of the 39–147 multi-subtype ligands. Its subtype selective ligand identification rates are significantly better than, and its multi-subtype ligand identification rates are comparable to the best rates of the previously used methods. Our method produced low false-hit rates in screening 13.56 M PubChem, 168,016 MDDR and 657,736 ChEMBLdb compounds. Molecular features important for subtype selectivity were extracted by using the recursive feature elimination feature selection method. These features are consistent with literature-reported features. Our method showed similar performance in searching estrogen receptor subtype selective ligands. Our study demonstrated the usefulness of the two-step target binding and selectivity screening method in searching subtype selective ligands from large compound libraries.

[1]  F. Sanz,et al.  Synthesis, 3D‐QSAR, and Structural Modeling of Benzolactam Derivatives with Binding Affinity for the D2 and D3 Receptors , 2010, ChemMedChem.

[2]  Andreas Bender,et al.  "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..

[3]  Peter Willett,et al.  Similarity searching using 2D structural fingerprints. , 2011, Methods in molecular biology.

[4]  Bing Xiong,et al.  Dopamine D1 receptor ligands: Where are we now and where are we going , 2009, Medicinal research reviews.

[5]  J. Ballesteros,et al.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.

[6]  Robert D. Clark,et al.  Using a staged multi-objective optimization approach to find selective pharmacophore models , 2009, J. Comput. Aided Mol. Des..

[7]  P. Jenner Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease , 2003, Current opinion in neurology.

[8]  Jean-Philippe Vert,et al.  Virtual screening with support vector machines and structure kernels , 2007, Combinatorial chemistry & high throughput screening.

[9]  M. Loza,et al.  Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif. , 2009, Bioorganic & medicinal chemistry letters.

[10]  Fabian Mörchen,et al.  Maximum Common Binding Modes (MCBM): Consensus Docking Scoring Using Multiple Ligand Information and Interaction Fingerprints , 2008, J. Chem. Inf. Model..

[11]  John P. Overington,et al.  Collation and data-mining of literature bioactivity data for drug discovery. , 2011, Biochemical Society transactions.

[12]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.

[13]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[14]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[15]  Alban Arrault,et al.  Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers , 2006, Molecular Diversity.

[16]  Teruki Honma,et al.  Combining Machine Learning and Pharmacophore-Based Interaction Fingerprint for in Silico Screening , 2010, J. Chem. Inf. Model..

[17]  Jia Jia,et al.  Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. , 2009, Combinatorial chemistry & high throughput screening.

[18]  Xin Chen,et al.  Effect of Molecular Descriptor Feature Selection in Support Vector Machine Classification of Pharmacokinetic and Toxicological Properties of Chemical Agents , 2004, J. Chem. Inf. Model..

[19]  Saso Dzeroski,et al.  Predicting gene function using hierarchical multi-label decision tree ensembles , 2010, BMC Bioinformatics.

[20]  Karine Audouze,et al.  New series of morpholine and 1,4-oxazepane derivatives as dopamine D4 receptor ligands: synthesis and 3D-QSAR model. , 2004, Journal of medicinal chemistry.

[21]  Johann Gasteiger,et al.  Comparison of Multilabel and Single-Label Classification Applied to the Prediction of the Isoform Specificity of Cytochrome P450 Substrates , 2009, J. Chem. Inf. Model..

[22]  Z R Li,et al.  Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins. , 2007, Journal of pharmaceutical sciences.

[23]  H. Verheij,et al.  Leadlikeness and structural diversity of synthetic screening libraries , 2006, Molecular Diversity.

[24]  Qi Wang,et al.  Subtype Selectivity of Dopamine Receptor Ligands: Insights from Structure and Ligand-Based Methods , 2010, J. Chem. Inf. Model..

[25]  Charles E. Heckler,et al.  Applied Multivariate Statistical Analysis , 2005, Technometrics.

[26]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[27]  Bernard F. Buxton,et al.  Support Vector Machines in Combinatorial Chemistry , 2001 .

[28]  John P. Overington ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. , 2009, Journal of computer-aided molecular design.

[29]  M. Millan,et al.  Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors , 2011, Neuropharmacology.

[30]  Gilles Marcou,et al.  Predicting the Predictability: A Unified Approach to the Applicability Domain Problem of QSAR Models , 2009, J. Chem. Inf. Model..

[31]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[32]  A. Rinken,et al.  N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. , 2009, Bioorganic & medicinal chemistry.

[33]  A. Gueiffier,et al.  Recent progress in medicinal chemistry of D4 agonists. , 2006, Current medicinal chemistry.

[34]  Vladimir N. Vapnik,et al.  The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.

[35]  X. H. Liu,et al.  Virtual Screening of Abl Inhibitors from Large Compound Libraries by Support Vector Machines , 2009, J. Chem. Inf. Model..

[36]  A. Newman,et al.  Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders , 2010, Annals of the New York Academy of Sciences.

[37]  Torsten Kuwert,et al.  Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands. , 2007, Journal of medicinal chemistry.

[38]  Peter Gmeiner,et al.  The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. , 2006, Pharmacology & therapeutics.

[39]  Y Z Chen,et al.  Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. , 2010, Molecular pharmaceutics.

[40]  Kyeong-Man Kim,et al.  Current perspectives on the selective regulation of dopamine D2 and D3 receptors , 2010, Archives of pharmacal research.

[41]  Y Z Chen,et al.  Combinatorial support vector machines approach for virtual screening of selective multi-target serotonin reuptake inhibitors from large compound libraries. , 2012, Journal of molecular graphics & modelling.

[42]  Grigorios Tsoumakas,et al.  Mining Multi-label Data , 2010, Data Mining and Knowledge Discovery Handbook.

[43]  J. Ross Quinlan,et al.  C4.5: Programs for Machine Learning , 1992 .

[44]  A. Argiolas,et al.  The Azulene Framework as a Novel Arene Bioisostere: Design of Potent Dopamine D4 Receptor Ligands Inducing Penile Erection , 2009, ChemMedChem.

[45]  Tudor I. Oprea,et al.  Scaffold Topologies. 2. Analysis of Chemical Databases , 2008, J. Chem. Inf. Model..

[46]  Andreas Bender,et al.  Analysis of Activity Space by Fragment Fingerprints, 2D Descriptors, and Multitarget Dependent Transformation of 2D Descriptors , 2006, J. Chem. Inf. Model..

[47]  Gajendra PS Raghava,et al.  RESEARCH ARTICLE Open Access Research article Prediction of cytochrome P450 isoform responsible , 2022 .

[48]  Bernard F. Buxton,et al.  Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..

[49]  Fabrizio Micheli,et al.  Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective , 2011, ChemMedChem.

[50]  Harald Hübner,et al.  Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. , 2009, Journal of medicinal chemistry.

[51]  Grigorios Tsoumakas,et al.  Multi-Label Classification: An Overview , 2007, Int. J. Data Warehous. Min..

[52]  Zhi-Hua Zhou,et al.  ML-KNN: A lazy learning approach to multi-label learning , 2007, Pattern Recognit..

[53]  Z R Li,et al.  MODEL—molecular descriptor lab: A web‐based server for computing structural and physicochemical features of compounds , 2007, Biotechnology and bioengineering.

[54]  C. Singer,et al.  A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[55]  P. Gmeiner,et al.  Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. , 2011, Trends in pharmacological sciences.

[56]  Jacob D. Durrant,et al.  Computer-aided drug-discovery techniques that account for receptor flexibility. , 2010, Current opinion in pharmacology.

[57]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[58]  Ao Zhang,et al.  Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. , 2007, Chemical reviews.

[59]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[60]  P. Jose,et al.  Dopamine Receptors: Important Antihypertensive Counterbalance Against Hypertensive Factors , 2011, Hypertension.

[61]  Stefan Schmitt,et al.  Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.

[62]  Z. R. Li,et al.  A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. , 2008, Journal of molecular graphics & modelling.

[63]  P. Gmeiner,et al.  1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. , 2009, Journal of medicinal chemistry.

[64]  R. Czerminski,et al.  Use of Support Vector Machine in Pattern Classification: Application to QSAR Studies , 2001 .

[65]  Yoshua Bengio,et al.  Collaborative Filtering on a Family of Biological Targets , 2006, J. Chem. Inf. Model..

[66]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[67]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[68]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[69]  B. Matthews Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.

[70]  Ron Kohavi,et al.  Wrappers for Feature Subset Selection , 1997, Artif. Intell..

[71]  Alan Talevi,et al.  Combined Virtual Screening Strategies , 2009 .

[72]  R. Mccall,et al.  Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease , 2005, Journal of Pharmacology and Experimental Therapeutics.

[73]  D. Sprous,et al.  QSAR in the pharmaceutical research setting: QSAR models for broad, large problems. , 2010, Current topics in medicinal chemistry.

[74]  T. Lue,et al.  The future is today: emerging drugs for the treatment of erectile dysfunction , 2010, Expert opinion on emerging drugs.